Physiopathologic evidences for early use of CPAP and exogenous surfactant in hyaline membrane disease;Pour ou contre une utilisation precoce de la pression positive continue nasale et du surfactant exogene au cours de la maladie des membranes hyalines. Arguments physiopathologiques

Archives de Pediatrie

Volumn 6, Issue 5, 1999, Pages 549-555

  Storme, L ^a   Truffert, P ^a   Rakza, T ^a   Lequien, P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

CPAP, nasal; Hyaline membrane disease; Pulmonary surfactants

Indexed keywords

LUNG SURFACTANT;

ARTIFICIAL VENTILATION; ATELECTASIS; HYALINE MEMBRANE DISEASE; LUNG DYSPLASIA; NEONATAL RESPIRATORY DISTRESS SYNDROME; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; REVIEW; TOTAL LUNG CAPACITY; TREATMENT PLANNING;

EID: 0033133482     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(99)80564-8     Document Type: Article

References (60)

1. Jonsson B, Katz-Salamon M, Faxelius G, Broberger U, Lagercrantz H. Neonatal care of very low-birthweight infants in special care units and neonatal intensive-care units in Stockholm. Early nasal continuous positive airway pressure versus mechanical ventilation: Gains and losses. Acta Paediatr 1997; 419 Suppl : 4-10.
2. Verder H, Robertson B, Greisen G, Ebbesen F, Albersen F, Lundstrom K, et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med 1994; 331 : 1051-5.
3. Millet V, Lacroze V, Bartoli JM, Samperiz S, Leclaire M, Unal D. Pression positive continue précoce en salle de travail. Arch Pédiatr 1997; 4 : 15-20.
4. Claris O, Salle BL, Lapillone A, Ronin E, Picaud JC, Besnier S. New technique of nasal continuous positive pressure in neonatology. Arch Pédiatr 1996; 3 : 452-6.
5. Reed GB, Claireaux AE, Bain AD. Diseases of the Fetus and Newborn. Baltimore: The CV Mosby Company; 1986. p. 254-69.
6. Bachofen H. Disturbance of alveolar lining layer: Effects on alveolar microstructure. J Appl Physiol 1994; 76 : 1983-9.
7. Jobe AH. Pathophysiology of respiratory distress syndrome ans surfactant metabolism. In: Polin RA, Fox WW, eds. Fetal and Neonatal Physiology. Vol. II. WB Saunders Company; 1998. p. 1299-314.
8. Pinkerton KE, Lewis JF, Rider ED, Peake J, Chen W, Madl AK, Lung parenchyma and type II cell morphometrics: Effect of surfactant treatment on preterm ventilated lamb lungs. J Appl Physiol 1994; 77 : 1953-60.
9. McCann EM, Goldman SL, Brady JP. Pulmonary function in the sick newborn infant. Pediatr Res 1987; 21 : 313-9.
10. Cotton RB. Pathophysiology of hyaline membrane disease (excluding surfactant). In: Polin RA, Fox WW, eds. Fetal and Neonatal Physiology. Vol. II. WB Saunders Company; 1998. p. 885-94.
11. Jackson JC, Mackenzie AP, Chi EY, Standaert TA, Truog WE, Hodson WA. Mechanisms for reduced totale lung capacity at birth and during hyaline membrane disease in premature monkeys. Am Rev Respir Dis 1990; 142 : 413-9.
12. Robertson B, Berry D, Curstedt T, Grossmann G, Ikegami M, Jacobs H, et al. Leakage of protein in the immature rabbit lung: Effect of surfactant replacement. Respir Physiol 1985; 61 : 265-76.
13. Berry D, Jobe A, Ikegami M. Leakage of macromolecules in ventilated and unventilated segments of preterm lamb lungs. J Appl Physiol 1991; 70 : 423-9.
14. Sundell HW, Harris TR, Cannon JR, Lindstrom DP, Green R, Rojas J, et al. Lung water and vascular permeability-surface area in premature newborn lambs with hyaline membrabne disease. Cir Res 1987; 60 : 923-32.
15. Seidner SR, Ikegami M, Yamada T, Rider ED, Castro R, Jobe AH. Decreased surfactant dose-response after delayed administration to preterm rabbits. Am J Respir Crit Care Med 1995; 152 : 113-20.
16. Ikegami M. Surfactant inactivation. In: Boynton BR, et al., eds. New Therapies for Neonatal Respiratory Failure. New York: Cambridge University Press; 1994. p. 36-48.
17. Ueda T, Ikegami M, Jobe AH. Surfactant subtypes: In vitro conversion, in vivo function, and effects of serum proteins. Am J Respir Crit Care Med 1994; 149 : 1254-9.
18. Wirtz HRW, Dobbs LG. Calcium mobilization and exocytosis after one mechanical stretch of lung epithelial cells. Science 1990; 250 : 1266-9.
19. Muscedere JG, Mullen JBM, Gan K, Slutsky AS. Tidal ventilation at low airway pressure can augment lung injury. Am J Respir Crit Care Med 1994; 149 : 1327-34.
20. Froese AB. Optimizing alveolar expansion prolongs the effectiveness of exogenous surfactant therapy in the adult rabbit. Am Rev Respir Dis 1993; 147 : 569-77.
21. Shapiro BA, Kacmarec RM, Cane RD, Peruzzi WT, Hauptman D. Clinical Application of Respiratory Care. Baltimore: Mosby Year Book; 1991.
22. The investigators of the Vermont-Oxford Trials Network Database Project. The Vermont-Oxford Trials Network: Very low birth weight outcomes for 1990. Pediatrics 1993; 91 : 540-5.
23. Roberston B. Pathology and pathophysiology of neonatal surfactant deficiency. In: Robertson B, et al., eds. Pulmonary Surfactant. Amsterdam: Elsevier Science Publishers; 1984. p. 383-413.
24. Grossmann G, Nilsson R, Robertson B. Scanning electron microscopy of epithelial lesions induced by artificial ventilation of the immature lung: The prophylactic effect of surfactant replacement. Eur J Pediatr 1986; 145 : 361-7.
25. Lachmann B. Combined effects of surfactant substitution and prolongation of inspired phase in artificially ventilated premature rabbits. Pediatr Res 1982; 16 : 921-8.
26. Dreyfuss D, Saumon G. Role of tidal volume, FRC, and end-inspiratory volume in the development of pulmonary edema following mechanical ventilation. Am Rev Respir Dis 1993; 148 : 1194-203.
27. Dreyfuss D, Soler P, Saumon G. Mechanical ventilation-induced pulmonary edema. Interaction with previous lung alterations. Am Rev Respir Crit Care Med 1995; 15 : 1568-75.
28. Imai Y, Kawano T, Miyasaka K, Takata M, Imai T, Okuyama K. Inflammatory chemical mediators during conventional ventilation and during high-frequency ventilation. Am J Respir Crit Care Med 1994; 150 : 1550-4.
29. Takata M, Abe J, Tanaka H, Kitano Y, Doi S, Kohsaka T, et al. Intraalveolar expression of tumor necrosis factor gene during conventional and high-frequency ventilation. Am J Respir Crit Care Med 1997; 156 : 272-9.
30. Bjorklund LJ, Ingimarsson J, Curstedt T, John J, Robertson B, Werner O, et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997; 42 : 348-55.
31. Bjorklund LJ, Curstedt T, Ingimarsson J, Larsson A, Robertson B, Svenningsen NW, et al. Lung injury caused by neonatal ressucitation of immature lambs - Relation to volume of lung inflations. Pediatr Res 1996; 39 : 326A.
32. Nilsson R, Grossmann G, Robertson B. Lung surfactant and the pathogenesis of neonatal bronchiolar lesions induced by artificial ventilation. Pediatr Res 1978; 12 : 249-55.
33. Jobe AH. Surfactant and pulmonary blood flow distributions following treatment of premature lambs with natural surfactant. J Clin Invest 1984; 73 : 848-56.
34. Venkitaraman AR. Enhancement of biophysical activity of lung surfactant extracts and phospholipids-apoprotein mixtures by surfactant protein A. Chem Phys Lipids 1990; 56 : 185-92.
35. Yukitake K, Brown CL, Schlueter MA, Clements JA, Hawgood S. Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo. Pediatr Res 1995; 37 : 21-8.
36. Strayer DS, Herting E, Sun B, Robertson B. Antibody to surfactant protein A increases sensitivity of pulmonary surfactant of inactivation by fibrinogen in vivo. Am J Respir Crit Care Med 1996; 153 : 1116-22.
37. Goldsmith LS, Greenspan JS, Rubenstein SD, Wolfson MR, Shaeffer TH. Immediate improvement in lung volume after exogenous surfactant: Alveolar recrutement versus increased distension. J Pediatr 1991; 119 : 424-9.
38. Transwel KA, Clubb RA, Smith BT, Boston RW. Individualised continuous distending pressure applied within 6 hours of delivery in infants with respiratory distress syndrome. Arch Dis Child 1980; 55 : 33-9.
39. Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993; 328 : 861-7.
40. Rider ED, Ikegami M, Whitsett JA, Hull W, Absolom D, Jobe AH. Treatment responses to surfactants containing natural surfactant proteins in preterm rabbits. Am Rev Respir Dis 1993; 147 : 669-78.
41. Ogawa A, Brown CL, Schlueter MA, Benson BJ, Clement JA, Hawgood S. Lung function, surfactant apoprotein content, and level of PEEP in prematurely delivered rabbits. J Appl Physiol 1994; 77: 1840-9.
42. Milner AD, Saunders RA, Hopkin IE. Relationship of intraoesophageal pressure to mouth pressure during the measurement of thoracic gas volume in the newborn. Biol Neonate 1978; 33 : 314-9.
43. Andreasson B, Lindroth M, Svenningsen NW, Drefeldt B, Jonsson G, Niklason L, et al. Measurement of ventilation and respiratory mechanics during continuous positive airway pressure (CPAP) treatment in infants. Acta Paediatr Scand 1989; 78 : 194-204.
44. Pedersen JE, Nielsen K. Oropharygeal and esophageal pressures during mono-and binasal CPAP in neonates. Acta Paediatr 1994; 83 : 143-9.
45. Moa G, Nilsson K, Zetterstrom H, Jonsson LO. A new device for administration of nasal continuous positive airway pressure in the newborn: An experimental study. Crit Care Med 1988; 16 : 1238-42.
46. Gherini S, Peters RM, Virgilio RW. Mechanical work of the lungs and the work of breathing with positive end expiratory pressure and continuous positive airway pressure. Chest 1979; 76 : 251-4.
47. Klausner JF, Lee AY, Hutchison AA. Decreased imposed work with a new nasal continuous positive airway pressure device. Pediatr Pulmonol 1996; 22 : 188-94.
48. Miller MJ, Difiore JM, Strohl KP, Martin RJ. Effects of nasal CPAP on supraglottic and total pulmonary resistance in preterm infants. J Appl Physiol 1990; 68 : 141-6.
49. Beaumont M, Lejeune D, Marotte H, Harf A, Lofaso F. Effects of chest wall counterpressures on lung mechanics under high levels of CPAP in humans. J Appl Physiol 1997; 83 : 591-8.
50. Kattwinkel J, Nearman HS, Fanaroff AA, Katona PG, Klaus MH. Apnea of prematurity. J Pediatr 1975; 86 : 588-92.
51. Miller MJ, Carlo WA, Martin RJ. Continuous positive airway pressure selectively reduces obstructive apnea in preterm infants. J Pediatr 1985; 106 : 91-4.
52. Locke R, Greenspan JS, Shaffer TH, Rubenstein SD, Wolfson MR. Effect of nasal CPAP on thoracoabdominal motion in neonates with respiratory insufficiency. Pediatr Pulmonol 1991; 11 : 259-64.
53. Zhang S, Garbutt V, McBride JT. Strain-induced growth of the immature lung. J Appl Physiol 1996; 81 : 1471-6.
54. Moa G, Nilsson K. Nasal continuous positive airway pressure: Experiences with a new technical approach. Acta Paediatr 1993; 82 : 210-1.
55. Jarreau PH, Farhat M, Desfrere L, Harf A, Moriette G. Nouvelles modalités d'utilisation de la PEP nasale. In : Journées de Néonatologie, Paris, 1996.
56. Robertson B, Lachmann B. Experimental evaluation of surfactants for replacement therapy. Exp Lung Res 1988; 14 : 279-87.
57. Morley CJ. Systematic review of prophylactic vs rescue surfactant. Arch Dis Child 1997; 77 : F70-4.
58. Robertson NJ, McCarthy LS, Hamilton PA, Moss ALH. Nasal deformities resulting from flow driver continuous positive airway pressure. Arch Dis Child 1996; 75 : F209-88.
59. Lundstrom KE, Greisen G. Early treatment with nasal CPAP. Acta Paediatr 1993; 82 : 856.
60. Mettey R, Masson G, Hoppeler A. Use of nasal cannula to induce positive expiratory pressure in neonatology. Arch Fr Pédiatr 1984; 41 : 117-21.